Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis

Affiliations

¹ a The First Department of Internal Medicine , School of Medicine, University of Occupational and Environmental Health , Japan, Kitakyushu , Japan.
² b Pfizer Inc , New London , CT , USA.

Free article

Comment

Yoshiya Tanaka et al. Mod Rheumatol. 2016.

Free article

. 2016;26(2):318-9.

doi: 10.3109/14397595.2015.1012799.

¹ a The First Department of Internal Medicine , School of Medicine, University of Occupational and Environmental Health , Japan, Kitakyushu , Japan.
² b Pfizer Inc , New London , CT , USA.

No abstract available

Comment on

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Tanaka Y, et al. Arthritis Care Res (Hoboken). 2011 Aug;63(8):1150-8. doi: 10.1002/acr.20494. Arthritis Care Res (Hoboken). 2011. PMID: 21584942 Clinical Trial.
Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company.
Minota S. Minota S. Mod Rheumatol. 2015 May;25(3):493-4. doi: 10.3109/14397595.2014.917600. Epub 2014 Jun 2. Mod Rheumatol. 2015. PMID: 24884482 No abstract available.